Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeNON PROFITSociety of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic

Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic

November 19, 2020

Society of Vascular and Interventional Neurology (SVIN) colleagues and Dr. James Siegler identify that it should come as no surprise that the COVID-19 pandemic and its many “waves” has led to significant paradigm shifts in medical care–from triage all the way to treatment, and SVIN and Dr. Siegler are releasing a study on Paradigm Shifts in Medical Care During COVID-19 Pandemic.

Many reports have indicated that patients are avoiding healthcare institutions to prevent contact with COVID-19 patients and healthcare professionals. Falling rates have been observed across a range of acute and critical conditions including myocardial infarction, stroke, and various cancers. The long-term consequences of healthcare avoidance remain unknown but will become clear in the coming months and years.

Using a novel lens to explore these indirect consequences of the COVID-19 pandemic, Dr. Siegler and colleagues from the Society of Vascular and Interventional Neurology undertook a multicenter observational study to evaluate the timeline of critical care that is provided to patients with acute ischemic stroke. These investigators pooled prospectively maintained data from 14 Comprehensive Stroke Centers (CSCs) in nine U.S. states between January 2019 and July 2020. Together, these nine states accounted for nearly half of all COVID-19 cases in the U.S. and more than one-third of all COVID-19-associated mortalities. (If any indirect effect of the pandemic were to influence the care of stroke patients, it would involve these high-risk geographical regions.)

Society of Vascular and Interventional Neurology note the objective of this investigation was to determine if patients were receiving standard-of-care reperfusion therapies (e.g., intravenous thrombolysis and/or thrombectomy) with the same expediency during the COVID-19 period as they were in the months prior.

Using the AHA Target: Stroke campaign goal of a 60-minute door-to-needle time for intravenous thrombolysis as a primary outcome, the authors found that patients admitted to these hospitals during the COVID-19 pandemic were at a 45% lower odds of being treated in that 60-minute time window (adjusted OR 0.55, 95%CI 0.35-0.85).

The investigators were also able to track the times from patient arrival to first neuroimaging to thrombolysis bolus. It appears that the principal mediator of the delay in thrombolysis was the delay in time from head imaging to bolus (median delay of seven minutes across all sites). Despite the increased need for personal protective equipment, contact precautions, and other barriers between patients and providers, there appeared to be no delay in time from arrival to first neuroimaging.

Furthermore, the delay in care appeared to persist throughout the months of June and July as the second wave of the pandemic spread across the southeastern and western United States. While the overall delay to thrombolysis was minimal (median delay of only four minutes), this delay was observed in CSCs, which are known to have faster throughput and treatment times when compared to other healthcare institutions. It is possible that this delay may be magnified in community hospitals, and these findings warrant exploration in non-CSC institutions.

Although there was a mild but significant delay in door-to-needle times during the COVID-19 pandemic, there appeared to be no significant delay in door-to-groin puncture times for patients who underwent endovascular recanalization during COVID-19. This may reflect the careful planning and anticipation of COVID-19 patient care by leaders within the Society of Vascular and Interventional Neurology, as their consensus guidelines had been published early during the pandemic.

Altogether, these findings suggest large scale gaps in acute medical care for a common neurological problem that affects almost 1 million Americans per annum. It is important for healthcare institutions to appraise their local paradigms in acute stroke care to determine if similar gaps exist, and what steps they can take to reduce delays in care during a global crisis. More on the Society of Vascular and Interventional Radiology here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy